Wall Street is unclear whether the U.S. insurance industry will have to pay any costs from the $4.69 billion verdict against Johnson & Johnson granted to customers and their families who alleged that asbestos-adulterated talc leads to ovarian cancer.
New sponsor OCA Ventures along with existing financiers have granted $1 million in Series A funding to PatientWisdom, a digital health corporation working on real-world data compilation tools. The company’s total funding is now worth $3.45 million.
Last year, around 100 veterans filed a bombshell lawsuit against several drugmakers, by accusing that they funded terrorism by paying high bribes to win contracts with the Iraqi Ministry of Health. At present, the Department of Justice is investigating similar accusations, as per AstraZeneca securities filing which says that it's part of the probe.
Wal-Mart had decided to leave the partnership with Castlight Health at the end of its current contract instead of transferring over to Castlight Complete, the company's new platform which was designed to bring the care navigation tools out to customers.
The German drugmaker Bayer has approved to sell its well-known prescription dermatology brands to Denmark’s Leo Pharma, as it focuses on integrating Monsanto also for strengthening its drug development pipeline.
Research in prostate cancer could speed up drastically with a new breakthrough in prostate cancer cells grown in-vitro which could transform future drug trials.
A research group from St.Petersburg Polytechnic University led by Professor Andrei Kozlov has published their study’s findings regarding HIV vaccine creation.
Ever heard of the dangers of kissing? The infection termed as ‘kissing disease’ is a viral infection which spreads through saliva which is where it gets its name from.
The DTP vaccine (diphtheria, tetanus, and pertussis – used to treat whooping cough), particularly two batches of it, were recalled in October 2017 as they tested unsuccessful, as per the British Columbia Centre for Disease Control.
Silencing an earlier known protein could hamper tumor development and increase the efficacy of immunotherapy treatments, researchers discovered at the Bloomberg~Kimmel Institute for Cancer Immunotherapy in the Johns Hopkins Kimmel Cancer Center.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.